Blueshift Asset Management LLC Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Blueshift Asset Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 34.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 652 shares of the company’s stock after selling 342 shares during the quarter. Blueshift Asset Management LLC’s holdings in Eli Lilly and Company were worth $503,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of LLY. Principal Financial Group Inc. raised its position in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the period. Quest Partners LLC raised its position in shares of Eli Lilly and Company by 29.2% during the 3rd quarter. Quest Partners LLC now owns 1,053 shares of the company’s stock valued at $933,000 after buying an additional 238 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $10,115,000. First Horizon Advisors Inc. raised its position in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 10,057 shares of the company’s stock valued at $8,910,000 after buying an additional 26 shares during the period. Finally, Moran Wealth Management LLC raised its position in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Moran Wealth Management LLC now owns 8,827 shares of the company’s stock valued at $7,820,000 after buying an additional 180 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Bank of America reaffirmed a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $843.35 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a fifty day simple moving average of $835.19 and a two-hundred day simple moving average of $840.70. The company has a market cap of $799.64 billion, a price-to-earnings ratio of 72.02, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.